0.00Open0.05Pre Close0 Volume3 Open Interest5.00Strike Price0.00Turnover737.85%IV1017.26%PremiumAug 16, 2024Expiry Date0.00Intrinsic Value100Multiplier16DDays to Expiry0.05Extrinsic Value100Contract SizeAmericanOptions Type0.2247Delta0.4289Gamma9.05Leverage Ratio-0.0063Theta0.0000Rho2.03Eff Leverage0.0003Vega
IGC Pharma Stock Discussion
Preclinical Analyses of Tgr-63 Demonstrate Blood-Brain Barrier Permeability and Safety Profile
Preclinical Analyses of TGR-63 Demonstrate Blood-Brain Barrier Permeability and Safety Profile
IGC Pharma has announced promising preclinical data for its drug candidate TGR-63, targeting Alzheimer’s disease. Studies indicate that TGR-63 can cross the blood-brain barrier, a critical challenge in treating Alzheimer's, as confirmed through mass spectrometry and an octanol-water assay. The drug also demonstrated a favorable safety profile, with no adverse effects observed i...
Benzinga· 3 mins ago
Anson Funds agreed to a $2.25 million settlement with the Securities and Exchange Commission (SEC) over a secret relationship with a short seller affecting two cannabis companies. The SEC found that while Anson Funds disclosed its short position strategy to investors, it did not reveal its collaboratio...
IGC Pharma Announces Patient Enrollment at Neurostudies in Phase 2 Trial Investigating IGC-AD1
Larger Image: tradingview.com...
$IGC Pharma(IGC.US)$
Get in on this
$IGC Pharma(IGC.US)$
No comment yet